News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Add-on immunotherapy prolongs survival in advanced endometrial cancer
03 Nov 2023
byJairia Dela Cruz
In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.
03 Nov 2023

Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
03 Nov 2023
byAudrey Abella
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
03 Nov 2023

Histologic inflammation of IBD a risk factor for serious infections
03 Nov 2023
Among individuals with inflammatory bowel disease (IBD), histologic inflammation appears to contribute to an increased risk of serious infections such as sepsis, according to a study, suggesting that achieving remission may reduce infections in IBD.
03 Nov 2023





